Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye

Therapies for macular degeneration and diabetic retinopathy require intravitreal injections every 4-8 weeks. Injections are uncomfortable, time-consuming, and carry risks of infection and retinal damage. However, drug delivery via noninvasive methods to the posterior segment of the eye has been a ma...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Control Release
Asıl Yazarlar: Anh Nguyen Huu, Viet, Luo, Jing, Zhu, Jie, Zhu, Jing, Patel, Sherrina, Boone, Alexander, Mahmoud, Enas, McFearin, Cathryn, Olejniczak, Jason, de Gracia Lux, Caroline, Lux, Jacques, Fomina, Nadezda, Huynh, Michelle, Zhang, Kang, Almutairi, Adah
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384820/
https://ncbi.nlm.nih.gov/pubmed/25571784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2015.01.001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller